Cosmo Pharmaceuticals NV

COPN

Company Profile

  • Business description

    Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.

  • Contact

    Sir John Rogerson’s Quay
    Riverside II
    Dublin2
    IRL

    T: +353 18170370

    E: investor.relations@cosmopharmaceuticals.com

    https://www.cosmopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    322

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries7,853.7060.20-0.76%
CAC 407,104.8021.22-0.30%
DAX 4020,374.10188.63-0.92%
Dow JONES (US)40,212.71619.051.56%
FTSE 1007,964.1850.930.64%
HKSE20,914.69232.911.13%
NASDAQ16,724.46337.142.06%
Nikkei 22533,585.581,023.42-2.96%
NZX 50 Index12,019.13182.30-1.49%
S&P 5005,363.3695.311.81%
S&P/ASX 2007,646.5063.10-0.82%
SSE Composite Index3,238.2314.590.45%

Market Movers